Skip to main content
. 2020 May 18;15(5):e0233176. doi: 10.1371/journal.pone.0233176

Fig 2. Effect of ET-1 and levosimendan in human PCLS.

Fig 2

A) Concentration-response curve of levosimendan in PAs and PVs: ○ naïve PAs (n = 5); □ naïve PVs (n = 6). B) Concentration-response curve of ET-1: ● naïve PAs (n = 7); ■ naïve PVs (n = 6). C) Concentration-response curve of levosimendan in ET-1 pre-constricted PAs: ○ 100 nM ET-1 (n = 6); ● 100 nM ET-1 / levosimendan (n = 6). D) Concentration-response curve of levosimendan in ET-1 pre-constricted PVs: □ 50 nM ET-1 (n = 7); ■ 50 nM ET-1 / levosimendan (n = 8). B: Statistics was performed by the comparison of EC50 values. P<0.05 are considered as significant.